

SPC Number	Owner of Certificate	Patent Title	Product	Active Ingredients	Date of Issue	Date of Expiry	MT Number	EP Number	Authorisation Number	PEC Number	PEC Expiry Date
001/2003	ICOS Corporation 22021 20th Avenue SE Bothell Washington 98021 / US	Tetracyclic derivatives, process of preparation and use	Cialis								
002/2004		Tetracyclic derivatives, process of preparation and use									
003/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	[R-(R*R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID,ITS LACTONE FORM AND SALTS THEREOF	LIPITOR™ - ATROVASTATIN						DE 38365.00/01/02/		
004/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	LACTAM FREE CYCLIC AMINO ACIDS	Neurontin	Neurontin					DE PL/0018/0202/02		
005/2004	Otsuka Pharmaceutical Co., Ltd., 2-9, Kanda-Tsukasacho Chiyoda-ku Tokyo / JP	LOW HYGROSCOPIC ARIPIRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF	Lyrica-Pregabalin	Lyrica-Pregabalin							
006/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	Asymmetric synthesis of pregabalin	Lyrica-Pregabalin	Lyrica-Pregabalin							
007/2007	Pfizer Products Inc. Eastern Point Road Groton Connecticut 06340 / US	POLYMORPHS OF A CRYSTALLINE AZOBICYCLO(2,2,2) OCTAN-3-AMINE CITRATE AND THEIR PHARMACEUTICAL COMPOSITIONS	Cerenia - Maropitant	Cerenia - Maropitant	05-Dec-07	18-Sep-21	1455	0	EU/2/06/062		
008/2008	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	TROPANE DERIVATIVES USEFUL IN THERAPY	Celsentri - maraviroc	Celsentri - maraviroc	17-Jul-08	20-Sep-22	1578	0	EU/1/07/418	PEC 3/2020	20/03/2023
009/2009	AstraZeneca AB 151 85 Södertälje / SE	Chemical process			25-Aug-09	14-Oct-23	2227	0	MA044/01502 - 03-04	PEC 8/2021	14/04/2024
010/2011	UCB Pharma GmbH Alfred-Nobel-Strasse 10 40789 Monheim / DE	STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE									
011/2013	Eisai R&D Management Co. Ltd. 6-10, Koishikawa 4-chome, Bunkyo-ku Tokyo 112-8088 / JP	CRYSTALS OF 1,2-DIHYDROPYRIDINE COMPOUND AND THEIR PRODUCTION PROCESS	Fycompa-Perampanel	Fycompa-Perampanel	04-Dec-13	23-Jul-27	2877	0			

012/2013	Almirall, S.A. Ronda General Mitre 151 08022 Barcelona / ES	PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO[2.2.2]OCTANE BROMIDE	Eklira Genuair-aclidinium bromide	aclidinium bromide	04-Dec-13	25-Jul-27	30031	2044067			
013/2013	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ / UK	INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES AND METHODS FOR THEIR USE	Inlyta-Axitinib	Inlyta-Axitinib	04-Dec-13	30-Jun-25	1473	0	EU/1/12/777		
014/2013	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ / UK	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors	XALKORI - crizotinib	XALKORI - crizotinib	04-Dec-13	26-Oct-27	2948	0			
015/2013	AstraZeneca AB SE- 151 85 Sodertalje / SE	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD	Forxiga-dapagliflozin	Forxiga-dapagliflozin	31-Jul-19	14-Nov-27	1907	0	C (2012) 8378	PEC 11/2022	14/05/2028
016/2013	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104 / US	STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES	Amyvid - Florbetapir (18F)	Amyvid - Florbetapir (18F)	04-Dec-13	17-Jan-28	30646	1999109	EU/1/12/805		
017/2013	Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF SYSTEMIC DISEASES IN CATS	Semintra-Telmisartan	Semintra-Telmisartan	07-Feb-14	13-Feb-28	31279	2086535	1	EU/2/12/146/00	
018/2013	Japan Tobacco Inc 2-1, Toranomom 2-chome Minato-ku Tokyo 105-8422 / JP	STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND	Stribild	elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil	07-Feb-14	27-May-28	2785	0	EU/1/13/830/00 1-002	PEC 10/2022	27/11/2028
019/2014	ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm / DE	METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF	Lonquex - lipegfilgrastim	Lonquex - lipegfilgrastim	15-Jul-14	25-Jul-28	31122	2144923	EU/1/13/856	PEC 19/2024	29/01/2029
020/2014	Novartis AG CH-4002 Basel / CH  Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH 12 5AB / UK	ORGANIC COMPOUNDS	Ultibro Breezhaler	Ultibro Breezhaler - Indacaterol maleate/glycopyrronium bromide	11-Sep-14	19-Sep-28	3071	0	EU/1/13/862		

021/2014	Mitsubishi Tanabe Pharma Corporation 3-2-10, Dosho-machi Chuo-ku, Osaka-shi Osaka 541-8505 / JP	CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5-(4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE	Invokana - canagliflozin	Canagliflozin hemihydrate	05-Sep-15	19-Nov-28	32142	2102224	EU/1/13/884		
022/2014	Biogen MA Inc. 250 Binney Street Cambridge, MA 02142 / US	Compositions and Uses for Treating Multiple Sclerosis	Tecfidera - Dimethyl fumarate	Dimethyl fumarate	ON HOLD		31523	2137537	EU/1/13/837		
023/2014	AstraZeneca AB SE- 151 85 Sodertalje / SE	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD	Xigduo	A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as protected by basic patent 1907	03-Dec-14	13-May-28	1907	1506211	EU/1/13/900		
024/2014	Janssen Pharmaceutica NV. Turnhoutseweg 30 2340 Beerse / BE	NOVEL MYCOBACTERIAL INHIBITORS	Sirturo	Bedaquiline, or a pharmaceutically acceptable acid or base addition of salt thereof, including bedaquiline fumarate	03-Dec-14	23-Jul-28	1948	0	EU/1/13/901		
025/2014	Glaxo Group Limited 980 West Road Brentford, Middlesex TW8 9GS / GB	MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS	INCRUSE	umeclidinium bromide	05-Sep-15	28-Apr-29	2735	0	EU/1/14/922		
026/2014							3660	0			
027/2014	MEDIVIR AB Lunastigen 7 141 44 Huddinge / SE	HCV NS-3 SERINE PROTEASE INHIBITORS	Olysio	Simeprevir, or a pharmaceutically acceptable salt thereof, including simeprevir sodium	05-Sep-15	14-May-29	2606	0	EU/1/14/924		
028/2014	Japan Tobacco Inc. 2-1, Toranomom 4-chome Minato-ku Tokyo 105-8422 / JP	PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF	Mekinist	Trametinib, optionally in the form of a pharmaceutically acceptable salt, hydrate or solvate thereof	05-Sep-15	02-Jul-29	2825	0	EU/1/14/931		
029/2014	Gilead Pharmasset LLC Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 / US  Gilead Sciences International LTD. Cambridge CB21 6GT / UK	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS	Sovaldi (sofosbuvir)	Sovaldi (sofosbuvir)	07-Dec-15	17-Jan-29	32301	2203462	EU/1/13/894	PEC 5/2021	17/07/2029

030/2015	Bristol-Myers Squibb Holdings Ireland Hinterbergstrasse 16 6312 Steinhausen / CH	HEPATITIS C VIRUS INHIBITORS	Daklinza	daclatasvir and pharmaceutically acceptable salts thereof, especially daclatasvir dihydrochloride	07-Dec-15	22-Aug-29	31906	2049522	EU/1/14/939/00 1-004		
031/2015	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	ANTIBODY FORMULATION	Gazyvaro	Obinutuzumab and all variants thereof	07-Dec-15	24-Jul-29	32047	2234600	EU/1/14/937		
032/2015	AbbVie Manufacturing Management Unlimited Company 70 Sir John Rogerson's Quay Dublin 2 / IE	ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF	Exviera - dasabuvir	dasabuvir, in all forms protected by the patent	07-Dec-15	15-Jan-30	30472	2203431	EU/1/14/983		
033/2015	AbbVie Manufacturing Management Unlimited Company 70 Sir John Rogerson's Quay Dublin 2 / IE	Hepatitis C virus inhibitors	Viekirax - ombitasvir / paritaprevir / ritonavir	Ombitasvir, in any form protected by the basic patent	16-Feb-16	15-Jan-30	31200	2368890			
034/2015	Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472 / US  AbbVie Manufacturing Management Unlimited Company 70 Sir John Rogerson's Quay Dublin 2 / IE	MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS	Viekirax - ombitasvir / paritaprevir / ritonavir	Paritaprevir, in any form protected by the basic patent	07-Dec-15	15-Jan-30	31870	2340029	EU/1/14/982		
035/2015	Kudos Pharmaceuticals Limited 2 Kingdom Street London W2 6BD / GB	POLYMORPHIC FORM OF 4-[3-(4- CYCLOPROPANECARBONYL-PIPERAZINE- 1-CARBONYL)-4-FLUORO-BENZYL]-2H- PHTHALAZIN-1-ONE	Lynparza - Olaparib	Olaparib	07-Dec-15	16-Dec-29	30503	2064189	EU/1/14/959 - 001		
036/2015	CELGENE CORPORATION 86 Morris Avenue Summit, NJ 07901 / US	SOLID FORMS COMPRISING (+)-2-[1-(3- ETHOXY-4-METHOXYPHENYL)-2- METHYLSULFONYLETHYL]-4- ACETYLAMINOISOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF	Otezla	Apremilast	SUSPENDED		31984	2276483	EU/1/14/981		

037/2015	Almirall, S.A. Ronda del General Mitre 151 08022 Barcelona / ES	NHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Brimica Genuair - aclidinium bromide / formoterol fumarate dihydrate	A combination of (a) formoterol, optionally in the form of its pharmacologically- compatible acid addition salts, especially formoterol fumarate, and (b) aclidinium in free or pharmaceutically acceptable salt form, especially aclidinium bromide	04-Jun-18	21-Nov-29	33206	2265257	EU/1/14/963		
038/2015	GALDERMA INTERNATIONAL Tour Europlaza, 20 avenue André Prothin La Défense 4, 92927 La Défense Cedex, PARIS / FR	USE OF IVERMECTINE FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS	Soolantra	Soolantra (active ingredient: Ivermectin for its use in the treatment of rosacea)	29-Nov-16	23-Apr-29	2197		EU/1/14/961 0 MA117-01101		
039/2015	EISAI R&D MANAGEMENT CO., LTD. 6-10 Koishikawa 4-chome Bunkyo-ku Tokyo 1128088 / JP	A crystalline form of the salt of 4-(3- chloro-4- )cyclopropylaminocarbonyl)aminophen oxy)-7-methoxy-6- quinolinecarboxamide or the solvate of the salt and a process for preparing the same	Lenvatinib	Levima (active ingedient: lenvatinib)	04-Mar-16	27-Dec-29	2557		EU/1/15/1002/0 01-002	PEC 24/2025	27/06/2030
040/2015	Novartis Europharm Limited Frimley Business Park Camberley GU 16 7SR / UK	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS	Zykadia - ceritinib	ceritinib or a pharmaceutically acceptable salt thereof	03-Nov-16	08-May-30	32135	2091918	EU/1/15/999		
041/2015	Novartis AG Lichtstrasse 35 4056 Basel / CH	COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS	Odomzo (sonidegib)	sonidegib or a pharmaceutically acceptable salt, hydrate of solvate thereof	21-May-18	18-Aug-30	31168	2021328	EU/1/15/1030		
042/2015	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS	Stribild	cobicistat or a pharmaceutically acceptable salt thereof	21-May-18	27-May-28	32628	2049506	EU/1/13/830	PEC 1/2008	27/11/2028
043/2016	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem / NL	ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1	Keytruda (pembrolizumab)	keytruda (pembrolizumab)	21-May-18	21-Jul-30	31674	2170959	EU/1/15/1024	PEC 9/2021	21/01/2031
044/2016	Gilead Pharmasset LLC 333 Lakeside Drive Foster City, CA 94404 / US	ANTIVIRAL COMPOUNDS	Harvoni (ledipasvir/sofosbuvir)	ledipasvir	21-May-18	18-Nov-29	33371	2430014	EU/1/14/958	PEC 4/2020	18/05/2030
045/2016	GlaxoSmithKline LLC Corporation Service Company 2711 Centreville Road Suite 400 Wilmington, Delaware 19808 / US	METHODS FOR ADMINISTERING ANTI- IL-5 ANTIBODIES	Nucala	mepolizumab	21-May-18	07-Dec-30	32454	2152290	EU/1/15/1043	PEC 2/2018	07/06/2031

046/2016	Novartis AG Lichtstrasse 35 4056 Basel / CH	SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE	Farydak	panobinostat or a pharmaceutically acceptable salt, or derivative thereof	21-May-18	01-Sep-30	33550	2032531	EU/1/15/1023		
047/2016	Novartis AG Lichtstrasse 35 4056 Basel / CH	ORGANIC COMPOUNDS	Entresto	Sacubitril/valsartan, as sacubitril valsartan sodium salt complex	SURRENDERED		3880	0	EU/1/15/1058		
048/2016	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	COMPOSITION FOR TREATING A PULMONARY HYPERTENSION	Volibris	Ambrisentan used in combination treatment with tadalafil	22-May-18	25-Nov-30	33049	2101777	EU/1/08/451		
049/2016	Alcafleu Management GmbH & Co. KG Lilienthalstrasse 4 12529 Schönefeld OT Waltersdorf / DE  Genzyme Corporation 50 Binney Street Cambridge, MA 02142 / US	TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H	Lemtrada	Alemtuzumab	22-May-18	16-Sep-28	33767	2066352	EU/1/13/869		
050/2016	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)	Repatha - Evolocumab	Evolocumab	15-Feb-21	21-Jul-30	33727	2215124	EU/1/15/1016	PEC 15/2023	21/01/2031
051/2016	PTC Therapeutics, Inc. 100 Corporate Court, Middlesex Business Center South Plainfield, NJ 07080 / US	CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID	Translarna	ataluren	22-May-18	05-Aug-29	33740	2076501	EU/1/13/902		
052/2016	Ardea Biosciences, Inc. 4939 Directors Place San Diego CA 92121 / US	NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE	Zurampic - lesinurad	lesurinad or a pharmaceutically acceptable salt thereof	22-May-18	22-Feb-31	32063	2217577	EU/1/15/1080		
053/2016	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)	Praluent-alirocumab	Alirocumab	WITHDRAWN		33727	2215124	EU/1/15/1031		
054/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US  Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab	05-Jun-18	13-May-31	32372	2068874	EU/1/16/1088		
055/2016							0	0			

056/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab combined with lenalidomide	05-Jun-18	13-May-31	32372	2068874	EU/1/16/1088		
057/2016							0	0			
058/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab combined with lenalidomide & dexamethasone	05-Jun-18	13-May-31	32372	2068874	EU/1/16/1088		
059/2016							0	0			
060/2016	Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512 / US	TREATMENT OPTIONS FOR FABRY DISEASE	Galafold	Migalastat or a salt thereof, including the hydrochloride salt	15-Jun-18	31-May-31	33453	2787345	EU/1/15/1082		
061/2016	BIAL - Portela & Ca., S.A. À Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado / PT	Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime	Ongentys - opicapone	Ongentys opicapone or a pharmaceutically acceptable salt thereof	18-Jun-18	28-Jun-31	33912	2481410	EU/1/15/1066		
062/2016	Horizon Therapeutics, LLC 150 S. Saunders Rd. Lake Forest IL 60045 / US	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS	Ravicti	Glycerol phenylbutyrate	15-Jun-18	01-Dec-30	34065	2330892	EU/1/15/1062		
063/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Genvoya	Cobicistat or a pharmaceutically acceptable salt thereof and tenofovir alafenamide or a pharmaceutically acceptable salt thereof, in particular tenofovir alafenamide fumarate	PATENT REVOKED		34208	2487166	EU/1/15/1061		
064/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Rezolsta	Cobicistat or a pharmaceutically acceptable salt or solvate thereof and darunavir or a pharmaceutically acceptable salt or solvate thereof, in particular darunavir ethanolate	PATENT REVOKED		34206	2487162	EU/1/14/967		

065/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Evotaz	Cobicistat or a pharmaceutically acceptable salt thereof and atazanavir or a pharmaceutically acceptable salt thereof, in particular atazanavir sulfate	PATENT REVOKED		34207	2487163	EU/1/15/1025		
066/2017	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS	Zepatier (grazoprevir)	Grazoprevir or a pharmaceutically acceptable salt thereof	15-Jun-18	26-Jul-31	30922	2310095	EU/1/16/1119		
067/2017	Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US	INHIBITORS OF HEPATITIS C VIRUS REPLICATION	Zepatier (elbasvir)	Elbasvir or a pharmaceutically salt thereof	20-Jul-18	26-Jul-31	33383	2410844	EU/1/16/1119		
068/2017	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID FORMS OF 3-(6-(1-(2,2- DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3- METHYLPYRIDIN-2-YL) BENZOIC ACID	Orkambi	3-{6-{{[1-(2,2-difluoro-1,3- benzodioxol-5- yl)cyclopropanecarbonyl]amino}} -3-methylpyridin-2-yl}benzoic acid	20-Jul-18	24-Nov-30	34064	2225230	EU/1/15/1059		
069/2017	Santen SAS 1, rue Pierre Fontaine Bâtiment Genavenir IV 91000 Evry / FR	COMPOSITIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS	Ikervis	Ciclosporin Anatomical main group: S - Sensory organs Therapeutic subgroup: S01 - Ophthalmologicals Pharmacological subgroup: S01X - Other ophthalmologicals Chemical subgroup: S01XA - Other ophthalmologicals Chemical substance: S01XA18- Ciclosporin	20-Jul-18	23-Mar-30	34398	2049079	EU/1/15/990		
070/2017	Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB	2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3- d]PYRIMIDIN-7-ON	IBRANCE - palbociclib - EU/1/16/1147	Palbociclib (optionally in the form of a pharmaceutically acceptable salt, ester, amide or prodrug thereof)	03-Aug-18	20-Dec-27	1836	0	EU/1/16/1147	PEC 22/2024	20-Jun-28
071/2017	Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 / JP	PROTEASOME INHIBITORS	Ninlaro - ixazomib	Ixazomib and pharmaceutically acceptable salts and esters thereof, such as ixazomib citrat	03-Aug-18	23-Nov-31	30821	2178888	EU/1/16/1094		
072/2017	Kai Pharmaceuticals, Inc. 270 Littlefield Avenue South San Francisco, CA 94080 / US	THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS	Parsabiv	Etelcalcetide, or a salt thereof, including etelcalcetide hydrochloride	03-Aug-18	15-Nov-31	34759	2459208	EU/1/16/1142		

073/2017	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE	Glyxambi	1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene(empagliflozin) in combination with 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (linagliptin) or a pharmace	03-Aug-18	15-Nov-31	34782	2187879	EU/1/16/1146/		
074/2017	AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence, Nassau / BS	APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES	Venclyxto	Venetoclax (Venclyxto)	03-Aug-18	07-Dec-31	33429	2435432	EU/1/16/1138		
075/2017	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US	MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOF	Vimizim	Elosulfase alfa	03-Aug-18	30-Apr-29	34199	2245145	EU/1/14/914		
076/2017	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY HUMAN ANTIBODIES TO PCSK9	Praluent - alirocumab	alirocumab	06-Aug-18	25-Sep-30	35197	2358756	EU/1/15/1031	PEC 17/2023	25-Mar-31
077/2017	Sanofi-Aventis Deutschland GmbH Brünningstraße 50 65929 Frankfurt am Main / DE	PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN, AND METHIONINE	Suliqua - insulin glargine / lixisenatide	Suliqua	06-Aug-18	13-Jan-32	32297	2498802	EU/1/16/1157		
078/2017	Chugai Seiyaku Kabushiki Kaisha 5-1, Ukima 5-chome Kita-ku Tokyo 115-8543 / JP	TETRACYCLIC COMPOUND	alectinib	Alectinib or salt or solvate thereof	16-Nov-18	20-Feb-32	33565	2441753	EU/1/16/1169		
079/2017	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANTICOAGULANT ANTIDOTES	Praxbind - Idarucizumab	Idarucizumab	06-Aug-18	24-Nov-30	34148	2525812	EU/1/15/1056	PEC 12/2022	24/05/2031
080/2017	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS	Olumiant - baricitinib	Baricitinib	06-Aug-18	15-Feb-32	34054	2288610	EU/1/16/1170		
081/2017	Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB	Chiral salt resolution	Xeljanz - Tofacitinib	Tofacitinib, optionally in the form of a pharmaceutically acceptable salt, including the citrate salt	23-Aug-18	30-May-27	1728	0	EU/1/17/1178		

082/2017	Corteva Agriscience LLC 9330 Zionsville Road, Indianapolis IN 46268 / US	NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS	NexGard - afoxolaner	Afoxolaner, or a pharmaceutically acceptable salt thereof	22-Aug-18	13-Feb-29	34662	2158188	EU/2/13/159		
083/2017	AbbVie Manufacturing Management Unlimited Company 70 Sir John Rogerson's Quay Dublin 2 / IE	An antiviral 1-phenyl-2,5- dibenzimidazol-5-yl-pyrrolidine derivative	Maviret - glecaprevir / pibrentasvir	Maviret pibrentasvir or a pharmaceutically acceptable salt thereof	13-Jul-18	28-Jul-32	33877	2692346	EU/1/17/1213	PEC 6/2021	28/1/2033
084/2017	Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472 / US	MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS	Maviret	Maviret glecaprevir or a pharmaceutically acceptable salt or ester thereof	13-Jul-18	28-Jul-32	33648	2618831	EU/1/17/1213	PEC 7/2021	28/1/2033
085/2017	Roche Glycart AG Wagistrasse 18 8952 Schlieren-Zuerich / CH	COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE	Gazyvaro - obinutuzumab	Obinutuzumab in combination with Bendamustine	22-Aug-18	15-Jun-31	34633	2464382	EU/1/14/937		
086/2017	Novartis AG Lichtstrasse 35 4056 Basel / CH  Astex Therapeutics Ltd. 436 Cambridge Science Park Milton Road Cambridge CB4 0QA / GB	PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS	Kisqali - ribociclib	Ribociclib or a pharmaceutically acceptable salt thereof	22-Aug-18	24-Aug-32	32026	2331547	EU/1/17/1221		
087/2017	REGENERON PHARMACEUTICALS, INC. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR	Kevzara - sarilumab	sarilumab	23-Aug-18	01-Jun-32	30593	2041177	EU/1/17/1196		
088/2017	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR	Dupixent - dupilumab	dupilumab	25-Aug-18	28-Sep-32	31371	2356151	EU/1/17/1229	PEC 14/2023	28/03/2033
089/2017	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION	Tecentriq - atezolizumab	atezolizumab	PATENT REVOKED		34913	2376535	EU/1/17/1220		

090/2018	Kirin-Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 / US	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	Kyntheum - brodalumab	An isolated antibody or fragment thereof comprising light chain and heavy chain CDR sequences according to EP-B1- 2076541 claim 1 (SEQ ID Nos: 224, 225, 226 and 146, 147, 148), wherein the antibody or fragment thereof binds human IL-17 receptor A; especial	07-Sep-18	19-Jul-32	32793	2076541	EU/1/16/1155		
091/2018					WITHDRAWN		32661	2365988			
092/2018	Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma / IT	Combination therapy for COPD	Trimbow - beclometasone / formoterol / glycopyrronium bromide	A combination of glycopyrronium bromide, formoterol or a salt thereof and beclometasone dipropionate	25-Aug-18	19-Jul-32	32121	2515855	EU/1/17/1208		
093/2018	Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP	PHARMACEUTICAL COMPOSITION	Lixiana - edoxaban	Edoxaban, a pharmaceutically acceptable salt thereof, or a hydrate of any of these, in particular Edoxaban p- toluenesulfonate monohydrate	25-Aug-18	23-Jun-30	35512	2140867	EU/1/15/993	PEC 21/2024	23-Dec-30
094/2018	Bayer Intellectual Property GmbH Alfred-Nobel-Strasse 10 40789 Monheim / DE	Combination therapy of substituted oxazolidinones	Xarelto - rivaroxaban	Xarelto	23-Aug-18	24-May-28	34999	2099453	EU/1/08/472		
095/2018	Nippon Shinyaku Co., Ltd. 14, Kisshoin Nishinosho Monguchicho Minami-ku Kyoto- shi Kyoto 607-8217 / JP	Crystals	Upravi - selexipag	Selexipag, which has the following formula: It has the IUPAC designation "2-{4-[(5,6- diphenylpyrazin-2- yl)amino]butoxy}-N- methanesulfonyl)acetamide"	19-Nov-18	19-May-31	35900	2447254	EU/1/15/1083		
096/2018	MSD Italia S.r.L. Via Vitorchiano 151 CAP 00189 Rome / IT	AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS	Zejula (Niraparib)	Niraparib or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, particularly the tosylate or a hydrate, especially the tosylate monohydrate	25-Aug-18	20-Nov-32	30300	2109608	EU/1/17/1235		
097/2018	Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK	GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES	Refixia - nonacog beta pegol	nonacog beta pegol	20-Nov-18	07-Jun-32	35932	2068907	EU/1/17/1193/0 01-002	PEC 29/2025	07-Dec-32

098/2018	Glaxo Group Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Trelegy Ellipta - fluticasone furoate/umeclidinium/vilanterol	A pharmaceutical combination product comprising a pharmaceutically acceptable salt of umeclidinium (e.g. umeclidinium bromide), vilanterol or a pharmaceutically acceptable salt thereof (e.g. vilanterol trifenate) and fluticasone furoate	22-Nov-18	17-Nov-32	35933	2506844	EU/1/17/1236		
099/2018	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOXOL DERIVATIVES	Steglatro - ertugliflozin	Ertugliflozin, optionally as a crystal form, particularly as a co-crystal with L-pyroglutamic acid, and specifically as Ertugliflozin L-pyroglutamic acid	22-Nov-18	23-Mar-33	30566	2334687	EU/1/18/1267		
100/2018	Kyowa Hakko Kirin Co., Ltd. 1-6-1, Ohtemachi Chiyoda-ku Tokyo 100-8185 / JP	Anti-FGF23 antibody and pharmaceutical composition comprising the same	CRYSVITA - Burosumab	Burosumab	22-Nov-18	14-Feb-33	35350	2502996	EU/1/17/1262		
101/2018	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	POLYCYCLIC-CARBAMOYLPIRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE	Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium	Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide	18-Dec-18	25-Dec-33	34020	2822954	EU/1/18/1289		
102/2018	GlaxoSmithKline Biologicals SA Rue de l'Institut 89 1330 Rixensart / BE	Vaccine	Shingrix	Varicella Zoster Virus (VZV) glycoprotein E (gE)	18-Dec-18	03-Mar-31	3328	0	EU/1/18/1272		
103/2018	VIIV Healthcare Company 251 Little Falls Drive Wilmington, DE 19808 / US	ANTIVIRAL THERAPY	Juluca - dolutegravir / rilpivirine	A combination comprising dolutegravir or a pharmaceutically acceptable salt thereof (e.g. dolutegravir sodium) and rilpivirine or a pharmaceutically acceptable salt thereof (e.g. rilpivirine hydrochloride)	29-Jan-19	18-May-33	36376	2932970	EU/1/18/1282		
104/2018	Kudos Pharmaceuticals Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, CB2 0AA / GB	PHARMACEUTICAL FORMULATION 514	Lynparza - Olaparib	Lynparza - Amorphous olaparib or a salt or solvate thereof, in a solid dispersion	SURRENDERED		33846	2346495	EU/1/14/959		

105/2018	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE	Rubraca - rucaparib	Rucaparib camsylate	29-Jan-19	29-May-33	34104	2534153	EU/1/17/1250		
106/2018	Vifor (International) Ltd. Rechenstrasse 37 9001 St.Gallen / CH	COMPOSITIONS COMPRISING CROSSLINKED CATION EXCHANGE POLYMERS AND USE IN TREATING HYPERKALEMIA	Veltassa - patiomer	Patiomer sorbitex calcium	25-Mar-19	21-Jul-32	36456	2957286	EU/1/17/1179		
107/2018	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	HUMAN CGRP RECEPTOR BINDING ANTIBODIES	Aimovig - erenumab	Erenumab	25-Mar-19	30-Jul-33	35226	2379594	EU/1/18/1293		
108/2019	Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US	MODULATION OF TRANSTHYRETIN EXPRESSION	Inotersen	A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of 20 linked nucleosides according to EP B1 2563920 claim 1 (SEQ ID NO: 80), wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked de	25-Mar-19	10-Jul-33	34488	2563920	EU/1/18/1296		
109/2019	Merck Sharp & Dohme LLC 126 East Lincoln Ave., P.O. Box 2000 Rahway, NJ 07065 / US	ENGINEERED ANTI-IL-23P19 ANTIBODIES	Ilumetri - tildrakizumab	tildrakizumab	25-Mar-19	21-Feb-33	30751	2059534	EU/1/18/1323		

110/2019	Medimmune Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA / GB	TARGETED BINDING AGENTS AGAINST B7-H1	Imfinzi - durvalumab	An antibody that binds to B7- H1 comprising a heavy chain CDR1 amino acid sequence of GFTFSRYWMS, a heavy chain CDR2 amino acid sequence of NIKQDGSEKYYVDSVKG, a heavy chain CD3 amino acid sequence of EGGWFGELAFDY, a light chain CDR1 amino acid sequence of RASQRVSSSYLA, a light chain CDR2 amino acid sequence of DASSRAT and a light chain CDR3 amino acid sequence of QQYGSLPWT, in particular Durvalumab, or a therapeutically equivalent variant thereof as protected by the basic patent	05-Aug-19	25-Sep-33	35158	2504364	EU/1/18/1322	PEC 18/2024	25/03/2034
111/2019	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6283 / US	USE OF CHIMERIC ANTIGEN RECEPTOR- MODIFIED T CELLS TO TREAT CANCER	Kymriah - tisagenlecleucel	tisagenlecleucel	21-Aug-19	27-Aug-33	35258	2649086	EU/1/18/1297		
112/2019	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6283 / US	USE OF CHIMERIC ANTIGEN RECEPTOR- MODIFIED T CELLS TO TREAT CANCER	Kymriah - tisagenlecleucel	tisagenlecleucel	WITHDRAWN		36501	3214091	EU/1/18/1297		

113/2019	Ardea Biosciences, Inc. 9390 Towne Centre Drive San Diego CA 92121 / US	TREATMENT OF GOUT AND HYPERURICEMIA	Allopurinol/Lesinurad	The Duzallo product includes the active ingredients allopurinol and lesinurad or a pharmaceutically acceptable salt or salts thereof	13-May-19	27-Aug-33	35824	2582683	EU/1/18/1300		
114/2019	Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US	Compositions and methods for inhibiting expression of transthyretin	Onpattro - patisiran	Onpattro (patisiran)	13-May-19	29-Aug-33	35371	2937418	EU/1/18/1320		
115/2019	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	PROTEIN KINASE INHIBITORS	Verzenio - abemaciclib	abemaciclib	13-May-19	01-Oct-33	31381	2379528	EU/1/18/1307		
116/2019	Tetraphase Pharmaceuticals, Inc. 480 Arsenal Street, Suite 110 Watertown, MA 02472 / US	C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS	Xerava - Eravacycline	Eravacycline or a pharmaceutically acceptable salt thereof	31-May-19	24-Sep-33	31386	2323972	EU/1/18/1312		
117/2019	Array BioPharma, Inc. 3200 Walnut Street Boulder CO 80301 / US	Compounds and Compositions as Protein Kinase Inhibitors	Mektovi - binimetinib	Binimetinib in combination with encorafenib, each optionally in the form of a pharmaceutically acceptable salt or solvate	01-Sep-20	24-Sep-33	34814	2727918	EU/1/18/1315		
118/2019	Array BioPharma, Inc. 3200 Walnut Street Boulder CO 80301 / US	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS	Braftovi - encorafenib	Encorafenib or a pharmaceutically acceptable salt or solvate thereof	23-Jun-20	24-Sep-33	31902	2470526	EU/1/18/1314		
119/2019	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	CGRP ANTIBODIES	Emgality - galcanezumab	galcanezumab	31-May-19	16-Nov-33	35641	2579894	EU/1/18/1330		
120/2019	ZS Pharma, Inc 508 Wrangler Dr., Suite 100 Coppell, TX 75019-7609 / US	USE OF A ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA	Lokelma - sodium zirconium cyclosilicate	sodium zirconium cyclosilicate	01-Jul-19	26-Mar-33	36657	2673237	EU/1/17/1173		
121/2019	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS	Symkevi - tezacaftor/ivacaftor	1-(2,2-difluoro-2H-1,3- benzodioxol-5-yl)-N-1-[(2R)- 2,3-dihydroxypropyl]-6-fluoro- 2-(1-hydroxy-2-methylpropan- 2-yl)-1H-indol-5- yl)cyclopropane-1-carboxamide	24-Jun-19	06-Nov-33	32832	2365972	EU/1/18/1306		

122/2019	Dyax Corp. 300 Shire Way Lexington, MA 02421 / US	PLASMA KALLIKREIN BINDING PROTEINS	Takhzyro - lanadelumab	An antibody comprising a VH sequence of EVQLLESGGGLVQPGGSLRLSCAA SGFTFSHYIMMWVRQAPGKGLE WVSGIYSSGGITVYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYY CAYRRIGVPRRDEFDIWGQGMV TVSS and a VL sequence of DIQMTQSPSTLSASVGRVTITCR ASQSISSWLAWYQKPGKAPKLLI YKASTLESGVPSRFSGSGSGTEF	24-Jun-19	26-Nov-33	36535	2521568	EU/1/18/1340		
123/2019	Ardenia Investments Ltd. First Floor 45 Welbeck Street London, Greater London W1G 8DZ / GB	DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES	Apealea - paclitaxel	paclitaxel micellar	01-Jul-19	22-Nov-33	35273	2231189	EU/1/18/1292		
124/2019	Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi Osaka / JP	PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS	Brigatinib	Brigatinib, or a pharmaceutically acceptable salt thereof	01-Jul-19	26-Nov-33	35531	2300013	EU/1/18/1264		
125/2019	Merck Canada Inc. 16711 Trans-Canada Highway Kirkland QC H9H 3L1 / CA	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	Pifeltro - doravirine	Doravirine or a pharmaceutically acceptable salt thereof	17-Jul-19	27-Nov-33	32413	2552902	EU/1/18/1332		
126/2019	Merck Canada Inc. 16711 Trans-Canada Highway Kirkland QC H9H 3L1 / CA	PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	DELSTRIGO (doravirine / lamivudine/tenofovir disoproxil)	Doravirine or a pharmaceutically acceptable salt thereof in combination with lamivudine or a pharmaceutically acceptable salt thereof in combination with tenofovir or an ester thereof, in particular a disoproxil ester or a pharmaceutically acceptable salt	17-Jul-19	26-Nov-33	34053	2924034	EU/1/18/1333		
127/2019	The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Erleada - apalutamide	apalutamide or a pharmaceutically acceptable salt thereof	01-Jul-19	27-Mar-32	31608	2368550	EU/1/18/1342		

128/2019	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3- D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)- 3- CYCLOPENTYLPROPANENITRILE	Ruxolitinib	A salt selected from the group consisting of ruxolitinib phosphoric acid salt, ruxolitinib sulfuric acid salt and ruxolitinib maleic acid salt	PATENT REVOKED		37182	3070090	EU/1/12/773		
129/2019	Pearl Therapeutics, Inc. 200 Saginaw Drive Redwood City, CA 94063 / US	RESPIRATORY DELIVERY OF ACTIVE AGENTS	Bevespi Aerosphere - glycopyrronium bromide / formoterol	A combination of glycopyrrolate (including any pharmaceutically acceptable salts, esters, enantiomers or other derivatives thereof) and formoterol (including any pharmaceutically acceptable salts, esters, enantiomers or other derivatives thereof)	31-Jul-19	20-Dec-33	34528	2435025	EU/1/18/1339		
130/2019	Warner-Lambert Company LLC 66 Hudson Boulevard East, New York, NY 10001-2192 / US	4-phenylamino-quinazolin-6-yl-amides	Vizimpro - dacomitinib	dacomitinib in the form of a monohydrate	18-Oct-19	26-Apr-30	2740		EU/1/19/1354		
131/2019	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES	Lorviqua-lorlatinib	Lorlatinib or a pharmaceutically acceptable salt thereof	18-Oct-19	08-May-34	34210	2822953	EU/1/19/1355		
132/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V /DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab	24-Feb-20	24-May-31	37533	2081595	EU/1/16/1101		
133/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, bortezomib and dexamethasone	24-Feb-20	03-May-32	37533	2081595	EU/1/16/1101		
134/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, lenalidomide and dexamethasone	24-Feb-20	03-May-32	37533	2081595	EU/1/16/1101		
135/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, bortezomib, melphalan and prednisone	24-Feb-20	26-Sep-32	37533	2081595	EU/1/16/1101		
136/2019	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US	COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF USING SAID COMPOSITIONS	Palynziq - pegvaliase	pegvaliase (Palynziq)	12-Nov-19	23-May-33	33084	2152868	EU/1/19/1362		

137/2019	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANTI-IL-23 ANTIBODIES	Skyrizi - risankizumab	Risankizumab	12-Nov-19	30-Apr-34	33812	2635601	EU/1/19/1361		
138/2019	Medivation Technologies LLC 525 Market Street, 36th Floor San Francisco, CA 94105 U.S.A.	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Talzenna-talazoparib		14-Jan-20	24-Jun-34	34614	2767537	EU/1/19/1377		
139/2019	Xencor, Inc. 465 North Halstead Street, Suite 200 Pasadena, CA 91107 / US	Fc variants with altered binding to FcRn	Ultomiris - Ravulizumab	Ultomiris - Ravulizumab	14-Jan-20	22-Dec-33	37868	2808343	EU/1/19/1371		
140/2019	Xencor, Inc. 465 North Halstead Street, Suite 200 Pasadena, CA 91107 / US	FC VARIANTS WITH ALTERED BINDING TO FCRN	Ultomiris - Ravulizumab	Ultomiris - Ravulizumab	14-Jan-20	22-Dec-33	32529	2235059	EU/1/19/1371		
141/2020	Astellas Pharma Inc. 5-1, Nihonbashi-Honcho 2- chome Chuo-ku Tokyo 103-8411 / JP  Kotobuki Pharmaceutical Co., Ltd. 6351, Oaza Sakaki Sakaki-machi Hanishina-gun, Nagano 389- 0697 / JP	DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND	Xospata-gilteritinib	gilteritinib or a salt thereof	12-May-20	28-Oct-34	33331	2428508	EU/1/19/1399		
142/2020	AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064 / US	NOVEL TRICYCLIC COMPOUNDS	Rinvoq - upadacitinib	upadacitinib	12-May-20	18-Dec-34	34901	2506716	EU/1/19/1404		
143/2020	Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	PYRAZOLO[1,5-]PYRIMIDINE COMPOUND AS TRK KINASE INHIBITOR	VITRAKVI - larotrectinib	Larotrectinib and/or pharmaceutically acceptable salts thereof, particularly larotrectinib sulfate including larotrectinib hydrogen sulfate	12-May-20	23-Sep-34	36251	3106463	EU/1/19/1385		

144/2020	Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US  COLD SPRING HARBOR LABORATORY Box 100, One Bungtown Road Cold Spring Harbor, NY 11724 / US	COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT	Spinraza - nusinersen	Nusinersen or salts thereof	12-May-20	01-Jun-32	38320	3449926	EU/1/17/1188		
145/2020	AstraZeneca AB 151 85 Södertälje / SE  AstraZeneca UK Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA / GB	BILAYER TABLET FORMULATIONS	Qtrilmet - metformin hydrochloride / saxagliptin / dapagliflozin	Metformin or a pharmaceutically acceptable salt thereof; saxagliptin or a pharmaceutically acceptable salt thereof; dapagliflozin or a pharmaceutically acceptable solvate thereof	09-Jun-20	13-Nov-34	36392	2498758	EU/1/19/1401		
146/2020	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS	Symtuza - Darunavir ethanolate / cobistat / emtricitabine / tenofovir alafenamide fumarate	Cobicistat or a pharmaceutically acceptable salt or solvate thereof, darunavir or a pharmaceutically acceptable salt or solvate of, in particular darunavir ethanolate, and emtricitabine or a pharmaceutically acceptable salt or solvate thereof	16-Jun-20	25-Sep-32	38094	3150586	EU/1/17/1225		
147/2020	Rigel Pharmaceuticals, Inc. 1180 Veterans Boulevard South San Francisco, CA 94080 / US	NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS	fostamatinib	Tavlesse - fostamatinib	23-Jun-20	13-Jan-35	37257	2736487	EU/1/19/1405		
148/2020	Recordati AG Lindenstrasse 8, 6340 Baar / CH	USE OF AN ADRENAL HORMONE-MODIFYING AGENT	Isturisa	Osilodrostat or a pharmaceutically acceptable salt thereof, including osilodrostat dihydrogen phosphate.	14-Sep-20	13-Jan-35	36588	2523731	EU/1/19/1407		
149/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST	Mayzent	Siponimod	14-Sep-20	21-Dec-34	33114	2379069	EU/1/19/1414		
150/2020	Helsinn Healthcare SA Via Pian Scairolo 9 6912 Lugano-Pazzallo / CH	SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES.	Akynzeo	'fosnetupitant and its pharmaceutically acceptable salts'	14-Sep-20	19-Mar-35	33931	2785706	EU/1/15/1001		

151/2020	Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES	Aservo EquiHaler - ciclesonide	Ciclesonide or a pharmaceutically acceptable salt thereof	14-Sep-20	30-Jan-35	36403	2934479	EU/2/19/249		
152/2020	AstraZeneca AB 151 85 Södertälje / SE	PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE	Qtern – saxagliptin / dapagliflozin	Saxagliptin and dapagliflozin	14-Sep-20	19-Jul-31	38379	2139494	EU/1/16/1108		
153/2020	Orion Corporation Orionintie 1 02200 Espoo / FI	ANDROGEN RECEPTOR MODULATING COMPOUNDS	NUBEQA - darolutamide	darolutamide	14-Sep-20	30-Mar-35	31955	2493858	EU/1/20/1432		
154/2020	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, bortezomib, thalidomide and dexamethasone	14-Sep-20	26-Sep-32	37533	2081595	EU/1/16/1101		
155/2020	Melinta Therapeutics, Inc. 44 Whippany Road Suite 280 Morristown, NJ 07960 / US	CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Vabomere – meropenem/vaborbactam	a combination of vaborbactam, and/or a salt and/or hydrate thereof, and meropenem, and/or a salt and/or hydrate thereof, in particular meropenem trihydrate	22-Sep-20	22-Nov-33	38648	3412676	EU/1/18/1334		
156/2020	Melinta Therapeutics, Inc. 44 Whippany Road Suite 280 Morristown, NJ 07960 / US	CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Vabomere – meropenem/vaborbactam	vaborbactam, and/or a salt and/or hydrate thereof	22-Sep-20	22-Nov-33	38648	3412676	EU/1/18/1334		
157/2020	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 / US	Anti-CD79b antibodies and immunoconjugates and methods of use	Polivy – polatuzumab Vedotin	Polatuzumab vedotin	14-Sep-20	15-Jul-33	32584	2474557	EU/1/19/1388		
158/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	Beta-lactamase Inhibitors	Recarbrio – imipenem / cilastatin / relebactam	relebactam, optionally in the form of the monohydrate, imipenem and cilastatin, optionally in the form of the sodium salt	22-Sep-20	15-Jan-34	32252	2666774	EU/1/19/1420		
159/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	Beta-lactamase Inhibitors	Recarbrio – imipenem / cilastatin / relebactam	relebactam, optionally in the form of the monohydrate, and imipenem	22-Sep-20	15-Jan-34	32252	2666774	EU/1/19/1420		
160/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	BETA-LACTAMASE INHIBITORS	Recarbrio – imipenem / cilastatin / relebactam	relebactam or a monohydrate thereof	22-Sep-20	15-Jan-34	31533	2231667	EU/1/19/1420		
161/2020	NOVARTIS AG Lichtstrasse 35, Basel 4056 / CH	STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF	Beovu - brolocizumab	brolocizumab	22-Sep-20	25-Jun-34	34642	2307454	EU/1/19/1417		
162/2020	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	BENZIMIDAZOLE DERIVATIVES	Daurismo - glasdegib	glasdegib, optionally in the form of a pharmaceutically acceptable salt, including the maleate salt	22-Sep-20	16-Jun-33	34062	2170860	EU/1/20/1451		

163/2020	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID	Orkambi – Lumacaftor / Ivacaftor	A combination of (a) 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and (b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof	22-Sep-20	24-Nov-30	38807	3170818	EU/1/15/1059		
164/2020	The Scripps Research Institute 10550 North Torrey Pines Road La Jolla, CA 92037 / US	NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS	Zeposia - ozanimod	Ozanimod or a pharmaceutically acceptable salt thereof, in particular ozanimod hydrochloride	22-Sep-20	14-May-34	38808	2913326	EU/1/20/1442		
165/2020	Receptos LLC Route 206 & Province Line Road, Princeton, New Jersey 08543 / US	SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS	Zeposia - ozanimod	Ozanimod or a pharmaceutically acceptable salt thereof, in particular ozanimod hydrochloride	22-Sep-20	25-May-35	36355	2498610	EU/1/20/1442		
166/2020	Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 / US  Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place New York, NY 10029 / US	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE	Givlaari - givosiran	Givosiran or a pharmaceutically acceptable salt thereof	29-Sep-20	04-Mar-35	38833	3052628	EU/1/20/1428		
167/2020	Nabriva Therapeutics GmbH Leberstrasse 20 1112 Wien / AT	PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES	Xenleta - lefamulin	Lefamulin, salts and solvates thereof	29-Sep-20	19-Mar-33	30511	2137143	EU/1/20/1457		
168/2020	Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 / JP	2-ACYLAMINOTHIAZOLE COMPOUND CRYSTALS	Doptelet - avatrombopag	Avatrombopag maleate (1-(3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexyl piperazin-1-yl)thiazol-2-yl] carbamoyl]pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt)	03-Nov-20	24-Jun-34	38705	3246325	EU/1/19/1373		
169/2020	Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma / IT	PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE	Lamzedo - velmanase alfa	alpha-mannosidase, in particular velmanase alfa	03-Nov-20	27-Mar-33	38945	3281636	EU/1/17/1258		

170/2020	Shionogi & Co., Ltd. 1-8, Doshomachi 3-chome Chuo-ku Osaka-shi Osaka 541-0045 / JP	CEPHALOSPORIN HAVING CATECHOL GROUP	Fetcroja - cefiderocol	Cefiderocol, optionally in the form of a pharmaceutically acceptable salt or solvate	24-Nov-20	27-Oct-34	33887	2960244	EU/1/20/1434		
171/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES	Piqray - alpelisib	Alpelisib or a pharmaceutically acceptable salt thereof	24-Nov-20	08-Sep-34	33793	2331537	EU/1/20/1455		
172/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST	Zeposia - ozanimod	Ozanimod	PATENT REVOKED		38057	3409274	EU/1/20/1442		
173/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS	Aectura Breezhaler - indacaterol / mometasone furoate Bemrist Breezhaler - indacaterol / mometasone furoate	indacaterol acetate or indacaterol xinafoate in combination with mometasone furoate	21-Dec-20	02-Jul-32	30926	2044025	EU/1/20/1438 - EU/1/20/1441		
174/2020	SANOFI 54, rue La Boétie 75008 Paris / FR	NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER	Sarclisa - isatuximab	isatuximab	29-Dec-20	16-Oct-32	37643	2076540	EU/1/20/1435		
175/2020	SANOFI 46 Avenue de la Grande Armée, 75017 Paris / FR  The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US	COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE	Sarclisa - isatuximab	isatuximab	05-Jan-21	03-Jun-35	37856	2928495	EU/1/20/1435		
176/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS	Energair Breezhaler - indacaterol / glycopyrronium / mometasone furoate Zimbus Breezhaler - indacaterol / glycopyrronium / mometasone furoate	Indacaterol acetate or indacaterol xinafoate, preferably indacaterol acetate, in combination with mometasone furoate and glycopyrronium	12-Jan-21	02-Jul-32	30926	2044025	EU/1/20/1438 - EU/1/20/1440		
177/2020	Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard, Boston, Massachusetts 02210 / US	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	Ondexxya - andexanet alfa	Andexanet Alfa	12-Jan-21	26-Sep-33	38778	3078743	EU/1/18/1345		
178/2020	Acceleron Pharma Inc. 128 Sidney Street Cambridge, MA 02139 / US	GDF TRAPS FOR USE TO TREAT ANEMIA	Reblozyl - luspatercept	Luspatercept in all its forms protected by the basic patent	12-Jan-21	13-Aug-34	37321	2340031	EU/1/20/1452		

179/2020	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	1' -substituted carba-nucleoside analogs for antiviral treatment	Veklury - remdesivir	Remdesivir or a pharmaceutically acceptable salt thereof	12-Jan-21	22-Apr-34	35616	2937350	EU/1/20/1459	PEC 27/2025	22/10/2034
180/2020	Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Bavencio - avelumab	avelumab	08-Feb-21	20-Sep-32	39064	2785375	EU/1/17/1214		
181/2021	Melinta Subsidiary Corp. 44 Whippany Road, Suite 280 Morristown, NJ 07960 / US	PROCESS FOR MAKING QUINOLONE COMPOUNDS	Quofenix - delafloxacin	delafloxacin or a salt or ester thereof, including delafloxacin meglumine	08-Mar-21	23-Sep-34	39088	3214083	EU/1/19/1393		
182/2021	SHIONOGI & CO., LTD 1-8, Doshomachi 3-chome Chuo-ku Osaka-shi Osaka 541-0045 / JP	ANTI-INFLUENZA POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF	Xofluza - baloxavir marboxil	baloxavir marboxil or a pharmaceutically acceptable salt thereof	01-Jun-21	08-Jan-36	39649	3428170	EU/1/20/1500	PEC 26/2025	08/07/2036
183/2021	Blueprint Medicines Corporation 45 Sidney Street Cambridge, MA 02139 / US	COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT	AYVAKYT - avapritinib	Avapritinib and pharmaceutically acceptable salts thereof	12-Apr-21	25-Sep-35	36548	3057969	EU/1/20/1473		
184/2021	Galapagos N.V. Generaal de Wittelaan L11 A3 2800 Mechelen / BE	5-PHENYL-[1,2,4]TRIAZOLO[1,5- A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS	Jyseleca - filgotinib	Filgotinib or a salt thereof	12-Apr-21	25-Jun-35	34666	2445911	EU/1/20/1480		
185/2021	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem / NL	4-IMIDAZOPYRIDAZIN-1-YL- BENZAMIDES AND 4-IMIDAZOTRIAZIN- 1-YL-BENZAMIDES AS BTK-INHIBITORS	Calquence - acalabrutinib	Acalabrutinib or a pharmaceutically acceptable salt thereof	01-Jun-21	06-Nov-35	37261	2734522	EU/1/20/1479		
186/2021	Novartis AG Lichtstrasse 35 4056 Basel / CH  Oklahoma Medical Research Foundation 825 N.E. 13th Street Oklahoma City, OK 73104 / US	Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases	Adakveo - crizanlizumab	crizanlizumab	01-Jun-21	30-Nov-32	36383	2662091	EU/1/20/1476		
187/2021	Scott & White Memorial Hospital 2401 South 31st Street Temple, TX 76508 / US	METHODS AND COMPOSITIONS BASED ON DIPHTHERIA TOXIN-INTERLEUKIN-3 CONJUGATES	ELZONRIS - tagraxofusp	tagraxofusp	01-Jun-21	07-Sep-32	38869	3207941	EU/1/20/1504		

188/2021	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE	Symkevi - tezacaftor/ivacaftor	A combination of (a) (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide or a pharmaceutically acceptable salt thereof and (b) N-(5-hydroxy-2,4-ditert-but	14-Jun-21	06-Nov-33	39448	2826776	EU/1/18/1306		
189/2021	Pearl Therapeutics, Inc. 200 Saginaw Drive Redwood City, CA 94063 / US	COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS	TRIXEO AEROSPHERE - Formoterol / glycopyrronium bromide / budesonide	A combination of formoterol (including any pharmaceutically acceptable salts, esters, solvates or enantiomers thereof), glycopyrrolate (including any pharmaceutically acceptable salts, esters, solvates or enantiomers thereof) and budesonide (including any	22-Jun-21	28-May-35	34511	2435024	EU/1/20/1498		
190/2021	Anylam Pharmaceuticals, Inc. 675 West Kendall Street Henri A. Termeer Square, Cambridge, MA 02142 / US	PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF	Leqvio - inclisiran	inclisiran	19-Jul-21	10-Dec-35	35301	2929031	EU/1/20/1494		
191/2021	Boehringer Ingelheim Animal Health USA Inc. 3239 Satellite Boulevard, Bldg. 500 Duluth, GA 30096 / US	PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHOD AND USES THEREOF	NexGard Combo - esafoxolaner / eprinomectin / praziquantel	A combination of Afoxolaner, Eprinomectin and Praziquantel	26-Jul-21	07-Jan-36	39159	3172964	EU/2/20/267		
192/2021	Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP	ANTI-HER2 ANTIBODY-DRUG CONJUGATE	Enhertu - trastuzumab deruxtecan	trastuzumab deruxtecan	26-Jul-21	20-Jan-36	36748	3101032	EU/1/20/1508		
193/2021	REGENERON PHARMACEUTICALS, INC. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 / US	VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION	Eylea - aflibercept ZALTRAP - aflibercept	Aflibercept	26-Jul-21	26-Nov-27	39323	2944306	EU/1/12/797; EU/1/12/814	PEC 13/2023	26/05/2028
194/2021	Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	SOLID DISPERSION	TUKYSA - tucatinib	tucatinib	23-Aug-21	12-Feb-36	35009	2765990	EU/1/20/1526		

195/2021	Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington, Massachusetts 02421 / US	METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA	Oxlumo - lumasiran	lumasiran	27-Sep-21	23-Nov-35	40103	3581654	EU/1/20/1496		
196/2021	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS	Pemazyre - pemigatinib	pemigatinib or a pharmaceutically acceptable salt thereof	11-Oct-21	29-Mar-36	34608	2861595	EU/1/21/1535		
197/2021	Amarin Pharmaceuticals Ireland Limited 2 Pembroke House Upper Pembroke Street 28-32 Dublin 2 / IE	COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY	Vazkepa - icosapent ethyl	icosapent ethyl	11-Oct-21	15-Jun-35	35466	2443246	EU/1/21/1524		
198/2021	Novartis AG Lichtstrasse 35 4056 Basel / CH	ANTI-CD20 ANTIBODY FORMULATIONS	Kesimpta - ofatumumab	ofatumumab	SURRENDERED		34756	2170388	EU/1/21/1532		
199/2021	Adverio Pharma GmbH Kaiser-Wilhelm-Allee 1 Leverkusen 51373 / DE	SUBSTITUTED 5-FLUORO-1H- PYRAZOLOPYRIDINES AND USE THEREOF	Verquvo - vericiguat	vericiguat	18-Oct-21	24-May-36	33377	2576547	EU/1/21/1561		
200/2021	AnaptysBio, Inc. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 / US	ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1)	JEMPERLI - dostarlimab	dostarlimab	18-Oct-21	22-Apr-36	39638	2992017	EU/1/21/1538		
201/2021	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF	Evkeeza - evinacumab	evinacumab	11-Oct-21	18-Jun-36	37137	2721065	EU/1/21/1551	PEC 25/2025	18/12/2036
202/2021	Karyopharm Therapeutics, Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 / US	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	NEXPOVIO - selinexor	selinexor	18-Oct-21	29-Mar-36	35920	2736887	EU/1/21/1537		
203/2021	CEV, S.A., Parque Tecnológico de Cantanhede Núcleo 04 Lote 2, 3060-197 Cantanhede / PT	USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDS	Aqueous extract from the germinated seeds of sweet Lupinus albus	BLAD protein	01-Nov-21	06-Apr-36	33923	2627177	(EU) 2021/567		
204/2021	Biocryst Pharmaceuticals, Inc., 4505 Emperor Blvd., Durham, North Carolina 27703 / US	TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS	Orladeyo - berotralstat	Berotralstat and pharmaceutically acceptable salts thereof	01-Nov-21	04-May-36	39507	3113772	EU/1/21/1544		

205/2021	Aragon Pharmaceuticals, Inc. 10990 Wilshire Blvd. Suite 300 Los Angeles, CA 90024 / US  Sloan Kettering Institute For Cancer Research 1275 York Avenue New York, NY 10065 / US	CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR	Erleada - apalutamide	Apalutamide	22-Nov-21	16-Jan-34	39863	3533792	EU/1/18/1342		
206/2021	AstraZeneca AB Sodertalje SE-151 85 / SE  Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	NOVEL HYDROGEN SULFATE SALT	Koselugo - selumetinib	Selumetinib (including any pharmaceutically acceptable salts [particularly hydrogen sulfate], esters, solvates or enantiomers thereof)	22-Nov-21	19-Dec-31	3995		EU/1/21/1552		
207/2021	Albireo AB Arvid Wallgrens Backe 20 413 46 Göteborg / SE	IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES	Bylvay - odevixibat	odevixibat	06-Dec-21	19-Jul-36	39029	3400944	EU/1/21/1566		
208/2021	Millenium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139 / US	ADENINE DERIVATIVE AS PI3K INHIBITOR	Copiktra - Duvelisib	duvelisib	06-Dec-21	15-Jul-35	32398	2456444	EU/1/21/1542		
209/2021	Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, 4th Floor, Cambridge MA 02138 / US	TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS	Copiktra - Duvelisib	duvelisib	06-Dec-21	21-May-36	36411	2914296	EU/1/21/1542		
210/2021	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, cyclophosphamide, bortezomib and dexamethasone	17-Jan-22	26-Sep-32	37533	2081595	EU/1/16/1101		
211/2021	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, pomalidomide, and dexamethasone	17-Jan-22	26-Sep-32	37533	2081595	EU/1/16/1101/0 01 - 002		
212/2022	UCB Biopharma SPRL Allée de la Recherche 60 1070 Brussels / BE	ANTIBODY BINDING IL-17A AND IL-17F	Bimzelx - bimekizumab	bimekizumab	14-Feb-22	23-Aug-36	35352	2663577	EU/1/21/1575		
213/2022	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	PYRROLO [2,3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK)	Cibinqo - abrocitinib	Abrocitinib, or a pharmaceutically acceptable salt thereof	28-Feb-22	10-Dec-36	34979	2958921	EU/1/21/1593		

214/2022	BEIGENE SWITZERLAND GMBH Aeschengraben 27, 4051 Basel / CH	FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS	Brukinsa - zanubrutinib	Zanubrutinib or a pharmaceutically acceptable salt thereof	07-Mar-22	23-Nov-36	34433	2989106	EU/1/21/1576		
215/2022	Xencor, Inc. 465 North Halstead Street, Suite 200 Pasadena, CA 91107 / US	OPTIMIZED ANTIBODIES THAT TARGET CD19	Minjuvi - tafasitamab	tafasitamab	14-Mar-22	14-Aug-32	31266	2383297	EU/1/21/1570		
216/2022	Galderma Research & Development Les Templiers 2400 Route des Colles, 06410 Biot / FR	NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS	Aklief 50 microgram/g cream	Trifarotene, optionally in the form of a pharmaceutically acceptable salt.	04-Apr-22	23-Dec-30	3207	0	MA117/01501		
217/2022	Alkermes Pharma Ireland Limited Connaught House 1 Burlington Road Dublin 4 / IE	PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES	Vumerity - diroximel fumarate	Vumerity (diroximel fumarate)	18-Apr-22	16-Nov-36	36774	2970101	EU/1/21/1585		
218/2022	ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S Tuborg Boulevard 12 2900 Hellerup / DK	NOVEL POLYMERIC HGH PRODRUGS	Lonapegsomatropin Ascendis Pharma - Lonapegsomatropin	Lonapegsomatropin Ascendis Pharma	16-May-22	17-Jan-37	40440	3653227	EU/1/21/1607		
219/2022	Deciphera Pharmaceuticals, LLC 643 Massachusetts, Suite 200 Lawrence, Kansas 66044 / US	DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	QINLOCK - ripretinib	Ripretinib or a pharmaceutical acceptable salt thereof	16-May-22	24-Nov-36	38512	3366293	EU/1/21/1569		
220/2022	Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50, 40789 Monheim am Rhein / DE	SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6- NAPHTHYRIDINAMIDES AND USE THEREOF	Kerendia - finerenone	Finerenone and its salts, solvates and solvates of the salts thereof	30-May-22	19-Feb-33	32564	2132206	EU/1/21/1616		
221/2022	Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri. A. Termeer Square Cambridge, MA 02142 / US	COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION	Oxlumo - lumasiran	Lumasiran, optionally in the form of a salt	13-Jun-22	23-Nov-35	40971	3204015	EU/1/20/1496		
222/2022	AstraZeneca AB 151 85 Södertälje / SE	ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY	Saphnelo - anifrolumab	anifrolumab	06-Jun-22	06-Feb-34	34237	2250279	EU/1/21/1623		
223/2022	Estetra SRL Rue Saint-Georges 5-7 4000 Liège / BE	ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT	Lydisilka - drospirenone / estetrol	drospirenone in combination with estetrol	27-Jun-22	20-May-36	41028	3701944	EU/1/21/1548		

224/2022	Janssen Biotech, Inc. 800/850 Ridgeview Drive Horsham, PA 19044 / US	BISPECIFIC EGFR/C-MET ANTIBODIES	Rybrevant - amivantamab	Rybrevant - amivantamab	27-Jun-22	10-Dec-36	36378	2922872	EU/1/21/1594		
225/2022	Apellis Pharmaceuticals, Inc. 100 5th Avenue Waltham, MA 02451 / US	LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS	ASPAVELI - Pegcetacoplan	Pegcetacoplan	27-Jun-22	14-Dec-36	40312	3660033	EU/1/21/1595		
226/2022	Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE	PYRIDAZINONE DERIVATES	Tepmetko - tepotinib	tepotinib and pharmaceutically usable solvates, salts, tautomers and stereoisomers thereof	18-Jul-22	29-Apr-33	32170	2164843	EU/1/21/1596		
227/2022	Fibrogen, Inc. 409 Illinois Street San Francisco, CA 94158 / US	CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR	Evrenzo - roxadustat	Roxadustat	18-Jul-22	19-Aug-36	41057	3470397	EU/1/21/1574		
228/2022	H. Lundbeck A/S Ottiliavej 9 2500 Valby / DK	ANTI-CGRP COMPOSITIONS AND USE THEREOF	Vyepti - eptinezumab	eptinezumab	18-Jul-22	25-Jan-37	40972	3495392	EU/1/21/1599		
229/2022	Laboratoires Juvise Pharmaceuticals 149, Boulevard Bataille de Stalingrad, 69100 Villeurbanne / FR	DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST	Ponvory - ponesimod	Ponesimod (IUPAC name: (R)-5- [3-chloro-4-(2,3-dihydroxy- propoxy)-benz[Z]ylidene]-2-([Z]- propylimino)-3-o-tolyl- thiazolidin-4-one) or pharmaceutically acceptable salts thereof	01-Aug-22	21-May-36	41142	3256125	EU/1/21/1550		
230/2022	Global Blood Therapeutics, Inc. 181 Oyster Point Blvd., South San Francisco, CA 94080 / US	SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION	Oxbryta - voxelotor	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof	22-Aug-22	15-Feb-37	35035	2797416	EU/1/21/1622		
231/2022	Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US	CGRP receptor antagonists	Vydura - rimegepant	Rimegepant or a pharmaceutically acceptable salt thereof	05-Sep-22	13-Oct-35	32008	2488512	EU/1/22/1645		

232/2022	PharmaEssentia Corp. 13F, No. 3. Park St. Nangang District Taipei 115 / TW	PROTEIN-POLYMER CONJUGATES	Besremi - ropeginterferon alfa-2b	ropeginterferon alfa-2b	26-Sep-22	15-Aug-33	41177	2205281	EU/1/18/1352		
233/2022	Agensys, Inc. 1 Astellas Way Northbrook, IL 60062 / US  Seagen Inc. 21823 30th Drive, S.E. Bothell, WA 98021 / US	ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS	Padcev - enfortumab vedotin	enfortumab vedotin	17-Oct-22	29-Sep-36	36108	2621526	EU/1/21/1615		
234/2022	Viela Bio, Inc. One MedImmune Way 5th Floor, Suite Area 2 Gaithersburg, MD 20878 / US	HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES	Uplizna - Inebilizumab	Inebilizumab	08-Nov-22	07-Sep-32	30706	2066349	EU/1/21/1602		
235/2022	Novartis AG Lichtstrasse 35 4056 Basel / CH	BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1	Scemblix - asciminib	Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride	14-Nov-22	26-Aug-37	35763	2861579	EU/1/22/1670		
236/2022	Genethon 1 bis rue de l'Internationale 91000 Evry / FR  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE 3, rue Michel Ange 75016 Paris / FR	WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL INJECTION OF AAV VECTORS	Zolgensma - onasemnogene abeparvovec	onasemnogene abeparvovec	05-Dec-22	03-Oct-33	41451	3505635	EU/1/20/1443		
237/2022	AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320 / US	ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN	Tezspire - tezepelumab	tezepelumab	02-Jan-23	09-Sep-33	33791	2205635	EU/1/22/1677		
238/2022	Incyte Holdings Corporation 1801 Augustine Cut-Off, Wilmington, DE 19803 / US	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS	Tabrecta - capmatinib	capmatinib or a pharmaceutically acceptable salt thereof	02-Jan-23	19-Nov-32	31047	2099447	EU/1/22/1650		

239/2023	CoLucid Pharmaceuticals, Inc. 2530 Meridian Parkway, Suite 300 Durham, NC 27713 / US	2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE FOR THE TREATMENT OF MIGRAINE VIA THE ORAL OR INTRAVENOUS ROUTE	RAYVOW - lasmiditan	Lasmiditan or a pharmaceutically acceptable salt thereof	23-Jan-23	02-Apr-35	35629	2413933	EU/1/21/1587		
240/2023	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US  University College London Gower Street London WC1E 6BT / GB  St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678 / US	AAV VECTORS COMPRISING A GENE ENCODING FACTOR VIII	valoctocogene roxaparvovec	valoctocogene roxaparvovec in all forms as protected by the basic patent	30-Jan-23	25-Aug-37	39930	3044231	EU/1/22/1168		
241/2023	Oncopeptides Innovation AB Luntmakargatan 46, 111 37 Stockholm / SE	LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES	Pepaxti - melphalan flufenamide	Melphalan flufenamide hydrochloride	30-Jan-23	25-Apr-37	35663	2701720	EU/1/22/1669/01		
242/2023	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	AMIDE COMPOUNDS FOR THE TREATMENT OF HIV	Sunlenca - lenacapavir	Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium	30-Jan-23	19-Aug-37	36339	2961742	EU/1/22/1671		
243/2023	Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US	Compositions and uses for treating Multiple Sclerosis	Tecfidera - Dimethyl fumarate	Tecfidera (dimethyl fumarate)			41688	2653873	EU/1/13/837		
244/2023	Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US	OPTIMIZATION OF HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF	Opdualag - nivolumab/relatlimab	relatlimab	13-Feb-23	16-Sep-37	34738	2867258	EU/1/22/1679	PEC 16/2023	16/03/2038
245/2023	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	GIP AND GLP-1 CO-AGONIST COMPOUNDS	Mounjaro - tirzepatide	tirzepatide and pharmaceutically acceptable salts thereof	13-Feb-23	19-Sep-37	37383	3242887	EU/1/22/1685		
246/2023	Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US	TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES	Amvuttra - vutrisiran	vutrisiran	27-Feb-23	16-Sep-37	39937	3329002	EU/1/22/1681		

247/2023	F. Hoffmann-La Roche AG Grenzacherstrasse 124, CH-4070, Basel / CH	BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES	Vabysmo - Faricimab	Faricimab	27-Feb-23	16-Sep-37	41062	3495387	EU/1/22/1683		
248/2023	Immunomedics Inc. 300 American Road Morris Plains, NJ 07950 / US	IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE	Trodelvy - sacituzumab govitecan	sacituzumab govitecan	06-Mar-23	02-Dec-34	41617	3912643	EU/1/21/1592		
249/2023	Janssen Biotech, Inc. 800/850 Ridgeview Drive, Horsham PA, 19044 / US	ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF	TECVAYLI - teclistamab	teclistamab	13-Mar-23	24-Aug-37	38803	3337824	EU/1/22/1675		
250/2023	Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 / US	QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY	Pyrukynd - mitapivat	Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate	15-May-23	29-Jun-35	33811	2448582	EU/1/22/1662		
251/2023	MEDIMMUNE LIMITED Milstein Building, Granta Park, Cambridge, CB21, 6GH / UK	RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF	Beyfortus - nirsevimab	nirsevimab	15-May-23	03-Nov-37	39256	3094353	EU/1/22/1689		
252/2023	ADC Therapeutics SA Route de la Corniche 3B 1066 Epalinges / CH  MedImmune Limited Milstein Building Granta Park Cambridge, Cambridgeshire CB21 6GH / GB	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	ZYNLONTA - loncastuximab tesirine	Loncastuximab tesirine in all forms protected by the basic patent	05-Jun-23	22-Dec-37	36389	2906298	EU/1/22/1695		
253/2023	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANTI IL-36R ANTIBODIES	Spevigo - spesolimab	spesolimab	19-Jun-23	14-Nov-37	37672	2780373	EU/1/22/1688	PEC 23/2025	14-May-38
254/2023	Wyeth LLC 66 Hudson Boulevard East New York, NY 10001-2192 / US	TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER	Nerlynx - neratinib	Neratinib	31-Jul-23	04-Sep-33	41821	3000467	EU/1/18/1311		
255/2023	uniQure biopharma B.V. Paasheuvelweg 25a 1105 BP Amsterdam / NL	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION	Hemgenix - etranacogene dezaparvovec	"Etranacogene dezaparvovec (an adeno-associated viral vector containing a codon- optimized Padua derivative of human coagulation factor IX gene for the treatment of hemophilia B)"	14-Aug-23	15-Sep-34	0	3581650	EU/1/22/1715		

256/2023	Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US	AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA	SOTYKTU (deucravacitinib)	Deucravacitinib or a pharmaceutically acceptable salt thereof	11-Sep-23	27-Mar-38	36377	2922846	EU/1/23/1718		
257/2023	Les Laboratoires Servier 50 rue Carnot 92284 Suresnes, Cedex / FR	LACTAM DERIVATES USEFUL AS INHIBITORS OF MUTANT IDH1	Tibsovo - ivosidenib	Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof	18-Sep-23	21-Jan-38	36565	2804851	EU/1/23/1728		
258/2023	Glaxo Group Limited GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY / UK	BCMA (CD269/TNFRSF17) - BINDING PROTEINS	BLENREP - belantamab mafodotin	belantamab mafodotin	09-Oct-23	26-Aug-35	42126	3415531	EU/1/20/1474		
259/2023	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	ANTIBODIES THAT BIND IL-23	OmvoH - mirikizumab	mirikizumab	16-Oct-23	30-May-38	39462	2964258	EU/1/23/1736		
260/2023	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US	PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS	AQUIPTA - atogepant	atogepant or a pharmaceutically acceptable salt thereof	06-Nov-23	10-Nov-36	32091	2638042	EU/1/23/1750		
261/2023	The Johns Hopkins University 3400 N. Charles Street Baltimore, MD 21218 / US	PSMA-BINDING AGENTS AND USES THEREOF	Pylclari - piflufolostat (18F)	piflufolostat (18F) or a pharmaceutically acceptable salt thereof	20-Nov-23	31-Jul-34	34765	2318366	EU/1/23/1746		
262/2023	Pfizer Inc. 66 Hudson Yards East New York, NY 10001 / US	PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES	Litfulo - ritlecitinib	Ritlecitinib	26-Dec-23	18-Sep-38	35162	3077395	EU/1/23/1755		
263/2023	MyoKardia, Inc. 1000 Sierra Point Parkway Brisbane California 94005 / US	PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS	CAMZYOS - mavacamten	Mavacamten or a pharmaceutically acceptable salt thereof	26-Dec-23	27-Jun-38	38571	3010910	EU/1/23/1716		
264/2023	Otsuka Pharmaceutical Co Ltd 2-9, Kanda Tsukasa-machi Chiyoda-ku Tokyo 101 8535 / JP	2'-FLUORO-2'- DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS	Inaqovi - decitabine / cedazuridine	A composition comprising: cedazuridine or a pharmaceutically acceptable salt thereof; and decitabine	22-Jan-24	16-Oct-33	30693	2207786	EU/1/23/1756		
265/2023	Otsuka Pharmaceutical Co Ltd 2-9, Kanda Tsukasa-machi Chiyoda-ku Tokyo 101 8535 / JP	2'-FLUORO-2'- DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS	Inaqovi - decitabine / cedazuridine	cedazuridine, or a pharmaceutically acceptable salt thereof	22-Jan-24	16-Oct-33	30693	2207786	EU/1/23/1756		
266/2024	BeiGene Switzerland GmbH Aeschengraben 27 4051 Basel / CH	ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS	Tevimbra (tislelizumab)	Tislelizumab	05-Feb-24	13-Sep-38	41289	3702373	EU/1/23/1758		

267/2024	Corteva Agriscience LLC 9330 Zionsville Road, Indianapolis, IN 46268 / US	FUNGICIDAL COMPOUNDS AND MIXTURES	Zorvec Vinabel	oxathiapiprolin or an N-oxide or salt thereof and zoxamide / oxathiapiprolin and zoxamide	05-Feb-24	23-Oct-33	35038	2187748	17248		
268/2024	Taiho Pharmaceutical Co., Ltd. 1-27, Kandanishiki-cho Chiyoda-ku Tokyo 101-8444 / JP	ANTITUMOR AGENT AND ANTITUMOR EFFECT ENHANCER	Lonsurf - trifluridine / tipiracil	Combination of trifluridine and tipiracil or a salt thereof with bevacizumab	12-Feb-24	27-Jul-38	42147	3042669	EU/1/16/1096		
269/2024	Loxo Oncology, Inc. Lilly Corporate Centre Indianapolis Indiana 46285 / US	COMPOUNDS USEFUL AS KINASE INHIBITORS	Jaypirca - pirtobrutinib	pirtobrutinib	11-Mar-24	31-Oct-38	38826	3390395	EU/1/23/1738		
270/2024	Takeda Vaccines, Inc. 75 Sidney Street Cambridge, MA 02139 / US  The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services 4770 Buford Highway Technology Transfer Office (K79) Atlanta, GA 30341 / US	COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES	Qdenga - dengue tetravalent vaccine (live, attenuated)	Dengue tetravalent vaccine (live, attenuated): Dengue virus serotype 1 (live, attenuated), wherein genes of serotype-specific surface proteins are engineered into dengue type 2 backbone Dengue virus serotype 2 (live, attenuated) Dengue virus serotype 3 (live, attenuated), wherein genes of serotype-specific surface proteins are engineered into dengue type 2 backbone Dengue virus serotype 4 (live, attenuated), wherein genes of serotype-specific surface proteins are engineered into dengue type 2 backbone	18-Mar-24	06-Dec-37	42488	4129330	EU/1/22/1699		
271/2024	Duke University 2812 Erwin Road, Suite 306 Durham, NC 27705 / US	TREATING BREAST CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS	ORSERDU - elacestrant	Elacestrant or a salt thereof	25-Mar-24	18-Sep-38	41762	3122426	EU/1/23/1757		

272/2024	Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	AN SGLT-2 INHIBITOR FOR USE IN THE TREATMENT OF A METABOLIC DISORDER IN FELINE ANIMALS	Senvelgo - velagliflozin	velagliflozin	25-Mar-24	22-Nov-38	42304	3862003	EU/2/23/305		
273/2024	Ambit Biosciences Corporation 211 Mount Airy Road, Basking Ridge, 07920 New Jersey / US	Spray dried formulation of AC220	VANFLYTA - quizartinib	quizartinib, i.e. N-(5-tert-butyl- 1,2-oxazol-3-yl)-N'-(4-{7-[2- (morpholin-4- yl)ethoxy]imidazo[2,1- b][1,3]benzothiazol-2- yl}phenyl)urea dihydrochloride	25-Mar-24	14-May-35	38461	2429524	EU/1/23/1768		
274/2024	Afferent Pharmaceuticals Inc. 126 East Lincoln Avenue Rahway New Jersey 07065 / US	DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH	Lyfnua - gefapixant	Gefapixant, or a pharmaceutically acceptable salt thereof	08-Apr-24	20-Sep-38	41963	3355889	EU/1/21/1613		
275/2024											
276/2024	Chugai Seiyaku Kabushiki Kaisha 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543 / JP	COMPOSITION FOR TREATING IL-6- RELATED DISEASES	Enspryng - satralizumab	satralizumab	06-May-24	29-Jun-36	42586	3263132	EU/1/21/1559		
277/2024	Reata Pharmaceuticals Holdings, LLC 5320 Legacy Drive, Plano, Texas 75024 / US	2.2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF	Skyclarys - omaveloxolone	omaveloxolone or a pharmaceutically acceptable salt thereof	06-May-24	24-Apr-38	35654	2841445	EU/1/23/1786		
278/2024	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS	Ebglyss - lebrikizumab	lebrikizumab	20-May-24	17-Nov-38	42121	3528838	EU/1/23/1765		
279/2024	ReveraGen BioPharma, Inc. 155 Gibbs Street, Suite 433 Rockville, MD 20850 / US	Non-hormonal steroid modulators of NF-KB for treatment of disease	AGAMREE - vamorolone	vamorolone	27-May-24	28-May-34	38411	2805720	EU/1/23/1776		
280/2024	UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE	ANTI-FCRN ANTIBODIES	Rystiggo-Rozanolixizumab	Rozanolixizumab	17-Jun-24	13-May-38	37174	2850101	EU/1/23/1780		
281/2024	RA Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 / US	MODULATION OF COMPLEMENT ACTIVITY	Zilbrysq - zilucoplan	zilucoplan	17-Jun-24	04-Dec-38	38508	3154561	EU/1/23/1764		
282/2024	Akebia Therapeutics, Inc. 245 First Street, Suite 1400, Cambridge, MA 02142 / US	COMPOSITIONS AND METHODS FOR TREATING ANEMIA	Vafseo	Vadadustat	17-Jun-24	25-Apr-38	42684	3007695	EU/1/23/1725		
283/2024	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION	Tecentriq - atezolizumab	Atezolizumab	17-Jun-24	25-Sep-32	42685	4209510	EU/1/17/1220	PEC 20/2024	25-Mar-33

284/2024	VIIV Healthcare Company 251 Little Falls Drive Wilmington, DE 19808 / US	COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION	Dovato - dolutegravir / lamivudine	dolutegravir or a pharmaceutically acceptable salt, including dolutegravir sodium, and lamivudine	17-Jun-24	03-Jul-34	42425	3494972	EU/1/19/1370		
285/2024	OGEDA NV Medialaan 50, 1800 Vilvoorde / BE	N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS	Veozza - fezolinetant	Fezolinetant	01-Jul-24	12-Dec-38	35460	2948455	EU/1/23/1771		
286/2024	Mirati Therapeutics, Inc. 3545 Cray Court San Diego, CA 92121 / US & Array Biopharma Inc. 3200 Walnut Street Boulder, CO 80301 / US	KRAS G12C INHIBITORS	Krazati-adagrasib	Adagrasib or a pharmaceutically acceptable salt thereof	01-Jul-24	09-Jan-39	42203	3710439	EU/1/23/1744		
287/2024	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES	Columvi-Glofitamab	Glofitamab	01-Jul-24	10-Jul-38	42726	3608337	EU/1/23/1742		
288/2024	Napp Pharmaceutical Group Limited, Unit 191 Cambridge Science Park, Milton Road, CB4 0GW Cambridge / UK	ANTIFUNGAL AGENTS AND USES THEREOF	Rezzayo-Rezafungin	Rezafungin or a pharmaceutically acceptable salt thereof, in particular rezafungin acetate	01-Jul-24	02-Mar-37	35498	2680873	EU/1/23/1775		
289/2024	Novartis AG Lichstrasse 35, 4056 Basel / CH	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER	Pluvicto - lutetium (177Lu) vipivotide tetraxetan	Lutetium ( <sup>177</sup> Lu) vipivotide tetraxetan	22-Jul-24	12-Dec-37	42747	4095130	EU/1/22/1703		
290/2024	GlaxoSmithKline LLC Corporation Service Company 251 Little Falls Drive, Wilmington DE 19808 / US	N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDI N-4-YL)BENZAMIDE HYDROCHLORIDE SALTS	Omjjara - momelotinib	momelotinib, including momelotinib dihydrochloride monohydrate	29-Jul-24	26-Jan-39	39703	3154950	EU/1/23/1782		
291/2024	Arena Pharmaceuticals, Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US	SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS	Velsipity - etrasimod	Etrasimod, or a pharmaceutically acceptable salt thereof, such as etrasimod arginine	19-Aug-24	22-Jul-34	33689	2326621	EU/1/23/1790		
292/2024	MacroGenics, Inc. 9704 Medical Center Drive Rockville, MD 20850 / US	PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF	ZYNYZ - retifanlimab	retifanlimab	19-Aug-24	24-Apr-39	41206	3328419	EU/1/24/1800		

293/2024	Novartis AG Lichtstrasse 35 4056 Basel / CH	PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS	FABHALTA - iptacopan	Iptacopan or a pharmaceutically acceptable salt thereof	14-Oct-24	21-May-39	35992	3022192	EU/1/24/1802		
294/2024	Ligand Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard Suite 110 San Diego, CA 92121 / US	A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY	Filspari - Sparsentan	Sparsentan or a pharmaceutically acceptable salt thereof	28-Oct-24	29-Mar-35	38374	3222277	EU/1/23/1788		
295/2024	Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US	COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION	Qalsody – tofersen	Tofersen	04-Nov-24	03-Jun-39	39605	3126499	EU/1/23/1783		
296/2024	uniQure biopharma B.V. Paasheuvelweg 25a 1105 BP Amsterdam / NL	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION	DURVEQTIX - fidanacogene elaparvovec	fidanacogene elaparvovec	18-Nov-24	15-Sep-34	43033	4032979	EU/1/24/1838		
297/2024	uniQure biopharma B.V. Paasheuvelweg 25a 1105 BP Amsterdam / NL	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION	Hemgenix - etranacogene dezaparvovec	A gene therapy that expresses the human coagulation Factor IX variant R338L	SURRENDERED		43033	4032979	EU/1/22/1715		
298/2024	Ascendis Pharma Bone Diseases A/S Tuborg Boulevard 12 2900 Hellerup / DK	PTH PRODRUGS	Yorvipath - palopegteriparatide	Yorvipath	18-Nov-24	20-Nov-38	43034	3423103	EU/1/23/1766		
299/2024	AstraZeneca AB 151 85 Södertälje / SE	PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS	Truqap - capivasertib	Capivasertib, optionally in the form of a pharmaceutically acceptable salt	25-Nov-24	09-Oct-33	32002	2201012	EU/1/24/1820		
300/2024	Bioverativ Therapeutics Inc. 225 Second Avenue Waltham MA 02451 / US	FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF	ALTUVOCT	efanesoctocog alfa or a similar biological medicinal product pursuant to Article 10(4) of Directive 2001/83/EC, as protected by the basic patent.	20-Jan-25	18-Jun-39	43111	4176894	EU/1/24/1824		
301/2024	Legend Biotech Ireland Limited One Spencer Dock North Wall Quay, Dublin 1 / IE	CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF	Carvykti	Ciltacabtagene autoleucl	20-Jan-25	22-Apr-39	42908	4063397	EU/1/22/1648		
302/2024	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT	Ordspono - odronextamab	odronextamab is an active ingredient of the medicinal product Ordspono	20-Jan-25	23-Aug-39	39559	3594238	EU/1/24/1843		
303/2024	LEO Pharma A/S Industriparken 55 2750 Ballerup / DK	USE OF DELGOCITINIB FOR THE TREATMENT OF CHRONIC HAND ECZEMA	Anzupgo - delgocitinib	Delgocitinib in all forms protected by the basic patent	20-Jan-25	23-Sep-39	42376	3405197	EU/1/24/1851		

304/2024	Hutchmed Limited Building 4, 720 Cailun Road, Pilot free Trade Zone, Shanghai, 201203 / CN	CRYSTALLINE FORMS OF 6-((6, 7-DIMETHOXYQUINAZOLIN-4-YL)OXY) - N,2- DIMETHYLBENZOFURAN-3-CARBOXAMIDE	FRUZAQLA - fruquintinib	fruquintinib	20-Jan-25	25-Jun-39	38769	3191475	EU/1/24/1827		
305/2024	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	SYSTEM, DEVICE AND METHOD FOR PREPARING TRACERS AND TRANSFERRING MATERIALS DURING RADIOSYNTHESIS	Tauvid - Flortaucipir (18F)	Flortaucipir	20-Jan-25	13-Apr-37	34320	2799091	EU/1/24/1799		
306/2025	WuXi Biologics (Shanghai) Co., Ltd. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 / CN WuXi Biologics Ireland Limited Mullagharlin Dundalk, Co Louth A91 X56F / IE	NOVEL ANTI-PD-L1 ANTIBODIES	Cejemly	sugemalimab	03-Feb-25	25-Jul-39	42290	3332006	88	EMA/H/C/0060	
307/2025											
308/2025	Astex Therapeutics Limited 436 Cambridge Science Park, Milton Road Cambridge Cambridgeshire, CB4 0QA / UK	PYRAZOLYL QUINOXALINE KINASE INHIBITORS	Balversa	Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof.	03-Mar-25	28-Apr-36	34452	2563775	EU/1/24/1841		
309/2025	Aegis Therapeutics, LLC 3430 Carmel Mountain Road, Suite 300 San Diego CA 92121 / US // ARS Pharmaceuticals Operations, Inc. 11682 El Camino Real, Suite 120 San Diego, CA 92130 / US	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	EURneffy-Epinephrine	Combination of epinephrine and dodecylmaltoside, in all forms protected by the basic patent	24-Mar-25	23-Aug-39	41587	3678649	EU/1/24/1846		
310/2025	Acceleron Pharma Inc. 126 East Lincoln Avenue, Rahway, New Jersey 07065 / US	COMPOSITIONS COMPRISING ACTRHA POLYPEPTIDES FOR USE IN TREATING PULMONARY HYPERTENSION	Winrevair (sotatercept)	Sotatercept	24-Mar-25	27-Aug-39	39959	3496739	EU/1/24/1850		
311/2025	Japan Tobacco, Inc. 1-1, Toranomom 4-chome Minato-ku Tokyo, 105-6927 / JP	NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME	Anzupgo - delgocitinib	Delgocitinib in all forms protected by the basic patent	24-Mar-25	30-Jul-35	34760	2460806	EU/1/24/1851		

312/2025	The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health 6701 Rockledge Drive Suite 700, MSC 7788 Bethesda, Maryland / US // Kite Pharma, Inc. 2400 Broadway Santa Monica, CA 90404 / US	METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF	Tecartus	autologous anti-CD19- transduced CD3+ cells (brexucabtagene autoleucel)	24-Mar-25	15-Dec-35	43256	3102609	EU/1/20/1492		
313/2025	Novartis AG Lichtstrasse 35 4056 Basel / CH	DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST	Zeposia - ozanimod	ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt	24-Mar-25	21-Dec-34	43259	4098256	EU/1/20/1442		
314/2025	ImmunoGen, Inc. 1 North Waukegan Road North Chicago, IL 60064 / US	IMMUNOCONJUGATES AGAINST FOLATE RECEPTOR 1 AND USES THEREOF	ELAHERE	mirvetuximab soravtansine	24-Mar-25	24-Feb-36	34196	2538976	EU/1/24/1866		
315/2025	Turning Point Therapeutics, Inc., Route 206 and Province Line Road, Princeton NJ 08543 / US	DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES	AUGTYRO-repotrectinib	Repotrectinib and/or pharmaceutically acceptable salts and esters thereof	21-Apr-25	14-Jan-40	41650	3572416	EU/1/24/1883		
316/2025	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel, Building 170, 3rd Floor, Main Quad, P.O. Box 20386, Stanford, California 94305-2038 / US	TRANSTHYRETIN STABILIZERS AND THEIR USE FOR INHIBITING TRANSTHYRETIN AMYLOIDOSIS AND PROTEIN-PROTEIN INTERACTIONS	BEYONTRA-acoramidis	Acoramidis, and/or a pharmaceutically acceptable salt thereof, especially acoramidis hydrochloride	21-Apr-25	18-Dec-38	36346	2934514	EU/1/24/1906		
317/2025	Achillion Pharmaceuticals, Inc. 121 Seaport Blvd. Boston MA 02210 / US	ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS	Voydeya – danicopan	Danicopan, or a pharmaceutically acceptable salt thereof	21-Apr-25	25-Apr-39	43212	4129407	EU/1/24/1792		
318/2025	Genmab A/S Carl Jacobsens Vej 30, DK-2500 Valby / DK	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, bortezomib, lenalidomide and dexamethasone	12-May-25	26-Sep-32	37533	2081595	EU/1/16/1101		

319/2025	Geron Corporation 919 E. Hillsdale Blvd. Foster City, CA 94404 / US	USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME	Rytelo - imetelstat	Imetelstat, or a pharmaceutically acceptable salt thereof	19-May-25	15-Nov-38	39080	3456333	EU/1/24/1894		
320/2025	Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104 / US	HIGHLY POTENT ACID ALPHA- GLUCOSIDASE WITH ENHANCED CARBOHYDRATES	cipaglucoisidase alfa	cipaglucoisidase alfa	09-Jun-25	24-Mar-38	43418	4273241	EU/1/22/1714		
321/2025	Yuhan Corporation, 74 Noryangjin-ro, Dongjak-gu, Seoul 06927 / KR	COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES	Lazcluze-lazertinib	lazertinib in all its forms protected by the basic patent	23-Jun-25	21-Jan-40	38977	3207035	EU/1/24/1886		
322/2025	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel / CH	ANTI-PD-L1 AN ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION	Tecentriq-atezolizumab	Atezolizumab	23-Jun-25	25-Sep-32	43442	4331604	EU/1/17/1220	PEC 28/2025	25-Mar-33
323/2025	CSL Behring Gmb Emil-von-Behring-Strasse 76 35041 Marburg / DE // CSL Limited 655 Elizabeth Street Melbourne VIC 3000 / AU	INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES	ANDEMBRY - garadacimab	garadacimab	11-Aug-25	20-Jul-37	43511	2734552	EU/1/24/1885		
324/2025	Peloton Therapeutics, Inc. 2330 Inwood Road Suite 226 Dallas, TX 75235-7323 / US	ARYL ETHERS AND USES THEREOF	WELIREG	Belzutifan, or a pharmaceutically acceptable salt thereof, particularly belzutifan.	11-Aug-25	05-Sep-39	38901	3417851	EU/1/24/1893		
325/2025											
326/2025	Genmab A/S Carl Jacobsens Vej 30 DK-2500 Valby / DK	HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR	Tivdak - Tisotumab vedotin	Tisotumab Vedotin	11-Aug-25	15-Jun-36	35851	2582728	EU/1/25/1911		
327/2025	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND USES THEREOF	LYNOZYFIC - linvoseltamab	Linvoseltamab	25-Aug-25	25-Apr-40	43503	3823664	EU/1/25/1917		
328/2025	CymaBay Therapeutics, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	TREATMENT OF INTRAHEPATIC CHOLESTATIC DISEASES	Lyvdelzi	Seladelpar or a pharmaceutically acceptable salt thereof, in particular seladelpar L-lysine dihydrate.	25-Aug-25	21-Feb-40	36816	3119384	EU/1/24/1898		
329/2025											
330/2025	BioArctic AB Warfvings väg 35 SE-112 51, Stockholm / SE	IMPROVED PROTOFIBRIL SELECTIVE ANTIBODIES AND THE USE THEREOF	LEQEMBI - lecanemab	lecanemab	06-Oct-25	23-Mar-32	30242	2004688	EU/1/24/1891		

331/2025	Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP // Sapporo Medical University 291-85, Minami 1-jo Nishi 17-chome Chuo-ku Sapporo-shi, Hokkaido 060- 8556 / JP	ANTI-TROP2 ANTIBODY-DRUG CONJUGATE	Datroway	datopotamab deruxtecan	06-Oct-25	24-Dec-39	36472	3088419	EU/1/25/1915		
332/2025	Genfit 885, Avenue Eugène Avinée 59120 Loos / FR	ELAFIBRANOR FOR USE IN THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS	Iqirvo - elafibranor	Elafibranor and pharmaceutically acceptable salts and esters thereof.	03-Nov-25	23-Sep-39	43653	3435996	EU/1/24/1855		
333/2025	Chugai Seiyaku Kabushiki Kaisha 5-1, Ukima 5-chome Kita-ku Tokyo 115-8543 /JP	PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT	Nemludio - Nemolizumab	Nemolizumab.	10-Nov-25	13-Feb-40	43683	3284480	EU/1/24/1901		
334/2025	Acerta Pharma B.V. Kloosterstraat 9 5349 AB Oss / NL	THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR	CALQUENCE - acalabrutinib	acalabrutinib or a pharmaceutically acceptable salt thereof, in combination with venetoclax optionally with or without obinutuzumab.	15-Dec-25	02-Jun-40	41248	3179991	EU/1/20/1479		
335/2025											
336/2025	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	METHODS OF TREATMENT FOR CYSTIC FIBROSIS	Alyftrek	a combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof.	05-Jan-26	01-Jul-40	42202	3880197	EU/1/25/1943		
337/2025	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM	Alyftrek	vanzacaftor, or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof.	05-Jan-26	01-Jul-40	41662	3752510	EU/1/25/1943		



349/2026	Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US	SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF	Ogsiveo - nirogacestat	Crystalline form of a hydrobromide salt of nirogacestat, preferably a crystalline form of the dihydrobromide salt of nirogacestat.	04-May-26	18-Aug-40	93722	4010322	EU/1/25/1932		
350/2026	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 / US	SELECTIVE ESTROGEN RECEPTOR DEGRADERS	Inluriyo - Imlunestrant	Imlunestrant.	04-May-26	13-Jan-41	41996	3820873	EU/1/25/2003		
351/2026	Astrazeneca AB 151 85 Södertälje / SE	(2S)-N-[(1S)-1CYANO-2PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Brinsupri	Brensocatib or its salts, hydrates, or hydrates of the salts, including brensocatib monohydrate.	04-May-26	23-Jan-40	35370	3097086	EU/1/25/1995		

As on 31 May 2026